DRREDDY - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.9
| Stock Code | DRREDDY | Market Cap | 1,09,236 Cr. | Current Price | 1,309 ₹ | High / Low | 1,380 ₹ |
| Stock P/E | 33.9 | Book Value | 376 ₹ | Dividend Yield | 0.61 % | ROCE | 12.7 % |
| ROE | 10.7 % | Face Value | 1.00 ₹ | DMA 50 | 1,284 ₹ | DMA 200 | 1,263 ₹ |
| Chg in FII Hold | -1.20 % | Chg in DII Hold | 0.28 % | PAT Qtr | -219 Cr. | PAT Prev Qtr | 90.6 Cr. |
| RSI | 52.6 | MACD | 13.0 | Volume | 20,23,440 | Avg Vol 1Wk | 20,17,890 |
| Low price | 1,148 ₹ | High price | 1,380 ₹ | PEG Ratio | 4.85 | Debt to equity | 0.18 |
| 52w Index | 69.3 % | Qtr Profit Var | -118 % | EPS | 38.6 ₹ | Industry PE | 30.5 |
📊 Financial Overview: Dr. Reddy’s Laboratories (DRREDDY) shows moderate fundamentals. ROE is 10.7% and ROCE is 12.7%, reflecting average efficiency. Debt-to-equity is low at 0.18, ensuring financial stability. Dividend yield is modest at 0.61%. Quarterly PAT turned negative (-₹219 Cr.) compared to ₹90.6 Cr. previously, showing a -118% variation, which raises concerns about earnings consistency.
💹 Valuation Indicators: Current P/E of 33.9 is slightly above the industry average of 30.5, suggesting premium valuation. P/B ratio is ~3.5 (1309/376), which is reasonable. PEG ratio of 4.85 signals limited growth relative to valuation. Intrinsic value appears lower than current price, implying cautious accumulation.
🏢 Business Model & Advantage: Dr. Reddy’s operates in pharmaceuticals, with strengths in generics, APIs, and biosimilars. Its competitive advantage lies in global presence, R&D capabilities, and diversified product portfolio. However, profitability pressures and earnings volatility limit near-term attractiveness.
📈 Entry Zone: A favorable entry zone lies between ₹1,200–1,250, closer to intrinsic value and support levels. Current price (₹1,309) is slightly above this zone, making staggered accumulation advisable.
🔒 Long-Term Holding Guidance: Dr. Reddy’s is a strong long-term play due to its global positioning and diversified portfolio. Despite earnings volatility and stretched valuations, its business moat supports resilience. Long-term investors can hold cautiously, monitoring profitability recovery and regulatory developments.
Positive
- 🌟 Strong global presence in generics and APIs
- 🌟 Low debt-to-equity (0.18)
- 🌟 Dividend yield modest but stable (0.61%)
- 🌟 DII holdings increased (+0.28%)
Limitation
- ⚠️ Quarterly PAT turned negative (-₹219 Cr.)
- ⚠️ ROE (10.7%) and ROCE (12.7%) relatively modest
- ⚠️ PEG ratio (4.85) signals limited growth
- ⚠️ P/E (33.9) slightly above industry average (30.5)
Company Negative News
- 📉 PAT dropped significantly (-118% variation)
- 📉 FII holdings reduced (-1.20%)
Company Positive News
- 📈 DII holdings increased (+0.28%)
- 📈 Strong industry positioning with diversified portfolio
Industry
- 🏦 Industry P/E at 30.5 reflects moderate valuations
- 🏦 Pharma sector supported by global demand for generics and biosimilars
Conclusion
✅ Dr. Reddy’s Laboratories has industry relevance and global presence, but negative earnings and modest return ratios limit attractiveness. A better entry zone lies between ₹1,200–1,250. Long-term investors should hold cautiously, awaiting profitability recovery and valuation corrections.
Would you like me to also prepare a global generics outlook to evaluate how international demand and regulatory trends could influence Dr. Reddy’s long-term trajectory?